Learn about the US Pharmaceutical Industry Report, 2008-2009
* Reuters is not responsible for the content in this press release.
NEW YORK--(Business Wire)-- Reportlinker.com announces that a new market research report is available in its catalogue. US Pharmaceutical Industry Report, 2008-2009 http://www.reportlinker.com/p0118600/US-Pharmaceutical-Industry-Report-2008-2009.html The United States has the largest pharmaceutical industry in the world. In 2007, its pharmaceutical revenue totaled at US$ 315 billion. In the past decades, the structure of American pharmaceutical industry has changed dramatically caused by the aging of population, the emerging of bio-pharmaceutical technology and fierce global competition. The key players in the United States including Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, etc. American pharmaceutical companies paid great attention to R & D due to the free market competition and patent protection of new medicines in the US. Since the year of 2000, the pharmaceutical R & D expenditure has been maintaining an increase, even in 2008, impacted by the global financial crisis, the pharmaceutical R & D expenditure totaled at US $65.2 billion, up 3.16% of last year. There are 2,900 drugs currently in research in US, among which 750 are anticancer drugs, 312 drugs are for heart diseases, 150 are diabetes drugs and 109 are AIDS drugs, the rest 91 drugs are for the Alzheimer and senile dementia diseases. In 2009, the sales growth of drugs in the United States is expected to around 1% ~ 2%. The growth of biotechnology, special drugs and generic drugs will be higher than the average. The report focus on the 30 pharmaceutical companies in the United States, including their profiles, revenue and profit, as well as their products, market distribution and development strategies. 1. Current Status and Prospects of US Pharmaceutical Industry 2. Pfizer Inc 3. Glaxo Smith Kline 4. Merck &Co. 5. Johnson & Johnson 6. Eli Lilly and Co 7. EpiCept Corporation 8. Schering Plough Corp 9. Forest Laboratories Inc 10. Mylan Inc 11. Herbalife Ltd 12. King Pharmaceuticals Inc 13. NBTY Inc 14. Perrigo Co 15. Life Technologies Corp 16. Sepracor Inc 17. Endo Pharmaceuticals Holdings Inc 18. Warner Chilcott Ltd 19. Par Pharmaceutical Companies Inc 20. Valeant Pharmaceuticals International 21. Chattem Inc 22. Prestige Brands Holdings Inc 23. Medicines Co 24. Techne Corp 25. Cambrex Corp 26. Allion Healthcare Inc 27. Salix Pharmaceuticals Ltd 28. PDL BioPharma Inc 29. Albany Molecular Research Inc 30.Enzon Pharmaceuticals Inc 31. AmerisourceBergen Corp Selected Charts Profit Pool of world`s pharmaceutical sector,2007 2007 Top companies by U.S Sales Biopharmaceutical Companies` investment in R&D, 1980-2008 R&D as a Percentage of Sales, PhRMA Member Companies, 2000-2008 Number of Compounds in Development, by Region* Domestic R&D Source, PhRMA Member Companies:2007 Biologics and Biotechnology R&D, PhRMA Member Companies:2007 2007 Channel Distribution by U.S Sales Pfizer Revenue by Business Segments,2006-2008 Change in Pfizer`s Revenues by Segment and Geographic Area, 2006-2008 Revenue and net profit of Pfizer Inc, 2004- 2008 Analysis of the Consolidated Statement of Income of Pfizer, 2006-2008 2008 Turnover summary,by segment GSK 2008 Turnover summary,by geography GSK Pharmaceutical turnover analysis,2007-2008 GSK Pharmaceutical key growth products,2007-2008 GSK Market share growth in Emerging Markets, 2008 GSK Product pipeline,2007-2008 Revenue and net profit of GSK, 2004- 2008 Financial performance of GSK, 2007-2008 Product sales of Merck, 2006-2008 Merck patent protection products Research pipeline of Merck as of Feb.15, 2009 Revenue and net profit of Merck, 2004- 2008 Sales of Johnson & Johnson, 1998-2008 Sales of Johnson & Johnson by Geographic Region, 1998-2008 Consumer segment sales of Johnson & Johnson, 2008 Consumer segment sales of Johnson & Johnson, 2006-2008 Pharmaceutical segment sales of Johnson & Johnson, 2008 Major Pharmaceutical Product revenues of Johnson & Johnson, 2006-2008 Medical Devices& Diagnostics segment of Johnson & Johnson, 2008 Major Medical Devices& Diagnostics Franchise sales of Johnson & Johnson, 2006-2008 R&D expense of Johnson & Johnson, 2006-2008 Johnson & Johnson Operating profit by segment, 2007-2008 Eli Lilly Eight Products Exceed $1 Billion in Net Sales, FY2008 Eli Lilly net sales activity of major products in 2007 compared with 2006 Eli Lilly products launched this decade Research and Development investment increasing, 2004-2008 Revenue and net profit of Eli Lilly, 2004- 2008 Return on Assets and shareholders` Equity Development Pipeline of main products of EpiCept Revenue and net profit of EpiCept, 2004- 2008 Net sales and Profit by segment, 2006-2008 Prescription pharmaceuticals sales of Schering Plough, 2007-2008 Revenue of Schering Plough by region Net sales and long-lived assets of Forest, 2006-2008 Net sales by therapeutic class of Forest Pipeline snapshot of Forest Strategically focused of Forest Revenue and net profit of Forest ,2004-2008 Financial highlights of Forest,2004-2008 Net sales and long-lived assets of Forest, 2006-2008 Comparison of 5 Year Cumulative Total Return, 2003-2008 Revenue composition of Mylan, 2007-2008 Mylan`s global market leadship, 2008 Significant operational properties of Mylan Revenue and net profit of Mylan,2004-2008 Comparison of cumulative total returns of Mylan`s Common Stock, the Standard & Poor`s 500 Composite Index and the Dow Jones U.S. Pharmaceuticals Index, 2003-2008 Sales of Herbalife by Geographic Region, 2007-2008 Sales by product category, 2007-2008 Revenue and net profit of Herbalife, 2004-2008 Comparison of cumulative total returns of Herbalife`s Common Stock, S& P 500 Composite Index and the Peer Index, 2004-2008 Revenue and net profit of King Pharmaceuticals, 2004-2008 Operating segments of NBTY, 2006-2008 Revenue and net profit of NBTY, 2004-2008 Comparison of 5 year cumulative total return among NBTY, Inc., NYSE Composite Index and The NYSE Care Index ,2003-2008 Perrigo revenue by country and by segment, 2008 Manufacturing scale of Perrigo, 2008 Sales, volumes and profits of Perrigo by category,2008 Updated category of Perrigo, 2008 Performance of Generic segment of Perrigo, 2008 Performance of API segment of Perrigo, 2008 R&D of Perrigo, 2004-2009 Revenue and net profit of Perrigo, 2004-2008 Perrigo financial performance,2003-2009 Revenue by geography of Life Technologies, 2008 Revenue by end markets of Life Technologies,2008 Basic data of Life Technologies, 2008 Revenue and net profit of Life Technologies,2004-2008 Comparison of 5-year cumulative total return among Life Technologies, NASDAQ market Index and NASDAQ Pharmaceutical Index, 2003-2008 Research and development pipeline of Sepracor,2008 Revenue and net profit of Sepracor,2004-2008 Product portfolio of Endo, 2008 Endo`s net sales by product category, 2006-2008 Revenue and net profit of Endo,2004-2008 Comparison of 5-year cumulative total return among Endo, NASDAQ market Index and NASDAQ Pharmaceutical Index, 2003-2008 Warner Chilcott`s revenues by product classes, 2006-2008 Revenue and net profit of Warner, 2005-2008 Revenue and net profit of Par,2004-2008 Product portfolio of Valeant Revenue breakout of Valeant,2008 Valeant revenue by product, 2007-2008 Valeant revenue of branded product, 2006-2008 Revenue and net profit of Valeant,2004-2008 Domestic net sales of Chattem, 2007-2008 Geographical segment information of Chattem, 2006-2008 Revenue and net profit of Chattem, 2004-2008 Prestige net revenue by segments, 2008 Revenue and net profit of Prestige, 2004-2008 Revenue and net profit of Medicines, 2004-2008 Products introduced by Techne, FY1989-2008 Results of Operations of Techne,2006-2008 Revenue and net profit of Techne, 2004-2008 Cambrex Gross sales by product groups, 2006-2008 Cambrex Gross sales by district, 2006-2008 Revenue and net profit of Cambrex, 2004-2008 Product mix of Allion, 2008 Allion Revenue of Specialty HIVand Specialty Infusion business, 2008 Allion Operating results of Specialty HIV segment,2007-2008 Revenue and net profit of Allion, 2004-2008 Net product revenues of Salix by product,2005-2007 Salix primary product candidates currently under development Strategy of Salix Revenue and net profit of Salix,2004- 2008 Comparison of 5-year cumulative total return among SLXP, NASDAQ composite Index and NASDAQ biotechnology Index, 2003-2008 The mix of U.S.-based sales and ex-U.S. based Manufacturing and Sales of PDL, 2006-2008 Revenue and net profit of PDL,2004-2008 Comparison of 5-year cumulative total return among PDL, NASDAQ biotechnology Index and NASDAQ composite Index, 2003-2008 Revenues of Albany Molecular by segment, 2006-2008 Revenue and net profit of Albany Molecular,2004-2008 Comparison of 5-year cumulative total return among Albany Molecular, NASDAQ Index and NASDAQ Pharmaceuticals Index, 2003-2008 ENZON Product portfolio + PIPELIN E ENZON segment profitability,2006-2008 ENZON sales performance by product,2006-2008 Revenue and net profit of Enzon,2004-2008 AmerisourceBergen revenue,FY 2008 Pharmaceutical distribution revenue of AmerisourceBergen ,2005-2008 Acquisition Strategy of AmerisourceBergen Revenue and net profit of AmerisourceBergen, 2004- 2008 FY 2008 Results of AmerisourceBergen Targets of AmerisourceBergen for fiscal year 2009 Long Term Financial Goals of AmerisourceBergen To order this report: US Pharmaceutical Industry Report, 2008-2009 http://www.reportlinker.com/p0118600/US-Pharmaceutical-Industry-Report-2008-2009.html More market research reports here! Reportlinker Nicolas: nbo@reportlinker.com US: (805)-652-2626 Intl: +1 805-652-2626 Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters